A new report into the German cannabis market estimates the total number of patients has risen 60,000 in less than two years since first approved for medical use.

The ‘Germany Cannabis Report’ from Prohibition Partners also states that within a few years that number will have risen to one million patients. And, it estimates the total German cannabis market will be worth €16.2 billion by 2028, with the medicinal cannabis market estimated to be worth €7.7 billion by the same time.

This comes as Canadian firm Aphria, one of the few from that country to be currently showing a profit, says that by next year Germany will be contributing almost half its revenues. 

Medical marijuana firm AMP German Cannabis Group announced that it will begin auditing its supply chain in accordance with the European Union (EU) Good Manufacturing Procedure (EU-GMP) to "ensure the quality and integrity of pharmaceutical goods" as they move through the supply chain from the supplier to the German patient.

Companies vying to be the biggest cannabis producer in America or Canada are wasting their time and suffering from a crippling lack of vision. The real play is to make a bid to become the worldwide leader in global cannabis exports — like firms in Jamaica and Lesotho as well as Canada are attempting to do — and the window of time to get in is closing fast, according to one entrepreneur with clear-cut plans to curb that market.

The first European deal for Canadian firm MediPharm Labs will see its medical cannabis products made available to 20,000 German pharmacies.

With dual listings on the Ontario and Frankfurt stock exchanges, MediPharm says this new deal is an important milestone in its global ambitions.

Patients in over 30 European countries could soon be able to get access to GW Pharmaceuticals Epidyolex cannabis medicine after it was approved by the European Commission.

Since its launch in the U.S last year GW’s sales have rocketed with Epidiolex (as it is known in America) boosting its revenues by over $30m in its first quarter, with more than 7,600 patients accessing the drug.

Now the European Medicines Agency has approved marketing authorisation in the 28 member states of the European Union, for its use for two conditions associated with childhood epilepsy; Lennox‑Gastaut syndrome and Dravet syndrome.

While Frankfurt is the current market of choice for overseas companies, the additional capital available in London will see it become Europe’s financial cannabis hub, say experts.

Jonathan Roy, a Director at the Cannabis Investor Forum, said the U.K. investment opportunities are currently limited to a few companies as others ‘play a waiting game’.

As the first annual German beer festival steins are downed there is reason to believe that 2020’s Oktoberfest offerings will come with an added twist.

Germany received its first imports of medicinal cannabis from Portugal and Australia this week. Two German companies took delivery of the shipments that will be used for testing purposes and to supply the country’s growing demand for medical marijuana, which was legalized in 2017.

In Cologne, Cannamedical Pharma received a commercial shipment of cannabis from a company in Portugal. Although the company did not identify the shipper, last month Tilray Portugal announced that it had come to an agreement with Cannamedical to export medicinal cannabis to Germany.

Marijuana is one of the fastest growing industries on the planet.

Eve & Co Incorporated (the “Company” or “Eve & Co”) (TSXV: EVE; OTCQB: EEVVF) is pleased to announce that its wholly-owned subsidiary Natural MedCo Ltd. has entered into a third binding, non-exclusive supply agreement for the sale of dried cannabis to a German importer and distributor.